anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Nuvectis Pharma · pitchdeck

Nuvectis Pharma | Investor Presentation Deck | 25 slides

25 pages · 7 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Nuvectis Pharma | Investor Presentation Deck | 25 slides

Nuvectis Pharma · 2024-01
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

7
coverage by narrative range · generated from this deck JSON
Narrative range 18 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Solution 3 slides 100% 3/3 slides 100% 3/3 slides · 17 hits
— 0/3 slides
100% 3/3 slides 33.3% 1/3 slides 100% 3/3 slides · 4 hits 100% 3/3 slides Traction 5 slides 100% 5/5 slides 100% 5/5 slides · 28 hits
— 0/5 slides
100% 5/5 slides 20% 1/5 slides 100% 5/5 slides · 7 hits 100% 5/5 slides · 7 hits Market Sizing 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides · 2 hits 100% 1/1 slides · 2 hits Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Solution 3 slides 100% 3/3 slides 100% 3/3 slides · 15 hits
— 0/3 slides
100% 3/3 slides 66.7% 2/3 slides 100% 3/3 slides 100% 3/3 slides Traction 4 slides 100% 4/4 slides 100% 4/4 slides · 20 hits
— 0/4 slides
100% 4/4 slides · 5 hits
— 0/4 slides
100% 4/4 slides 75% 3/4 slides

Slide inventory

25
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
summarize
Open slide detailLoop · Cost Of Inaction
04
The slide uses a visual layout to associate each executive with specific past pharmaceutical successes.other
Open slide detailLoop · Cost Of Inaction
05
The slide uses a table-like structure to represent a clinical trial roadmap, incorporating regulatory designations and partner logos.plan_implementation
Open slide detailLoop · Cost Of Inaction
06
transition
Open slide detailBeat · ProblemLoop · Cost Of Inaction
07
Includes a biological pathway diagram and a dose-response curve showing target validation.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
08
The slide presents experimental evidence (Western blot) supporting the mechanism of action for NXP800 in ARID1a-deficient cancer cells.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
09
Includes two line charts showing tumor volume reduction over time and a table showing patient incidence for target indications.show_traction
Open slide detailBeat · SolutionLoop · Cost Of Inaction
10
Includes a patient-derived xenograft (PDX) study methodology diagram and a line chart showing tumor volume over time.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
11
The slide presents three separate line charts showing tumor growth inhibition over time for different cell lines (RL95-2, KLE, SNG-M).show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
12
The slide uses a patient selection strategy based on ARID1a mutation status.size_opportunity
Open slide detailBeat · TractionLoop · Cost Of Inaction
13
The slide uses a split-column layout to contrast two phases of a clinical trial.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
14
transition
Open slide detailBeat · ProblemLoop · Voice Of Customer
15
summarize
Open slide detailBeat · SolutionLoop · Voice Of Customer
16
The charts are kinome dendrograms (KinomeScan style).compare_peers
Open slide detailBeat · SolutionLoop · Voice Of Customer
17
The slide uses a structural biology mechanism of action (MOA) comparison to demonstrate competitive advantage.present_solution
Open slide detailBeat · SolutionLoop · Voice Of Customer
18
Includes a biological pathway diagram and an IC50 dose-response curve.present_solution
Open slide detailLoop · Voice Of Customer
19
Data shows tumor regression in treated groups vs growth in control groups over 27 days.show_traction
Open slide detailBeat · TractionLoop · Voice Of Customer
20
Includes two distinct experimental setups: in vitro proliferation assays and in vivo bioluminescence imaging (BLI) tumor growth studies.present_solution
Open slide detailBeat · TractionLoop · Voice Of Customer
21
The table segments indications by Squamous cell prevalence and NF2 mutation prevalence.size_opportunity
Open slide detailBeat · TractionLoop · Voice Of Customer
22
Clinical trial identifier NCT05873686 is provided.show_traction
Open slide detailBeat · Traction
23
show_traction
Open slide detail
24
The slide uses a chevron-based list layout to categorize key highlights.summarize
Open slide detail
25
front_matter
Open slide detail